Skip to main content

Table 2 Prevalence of mutations in the MAPK pathway in ATC

From: Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review

Mutation

Positive/ total cases

Prevalence (%)

Reference

BRAF V600E

0/7

0

[51]

 

2/6

33

[52]

 

3/29

10

[53]

 

2/10

20

[54]

 

8/16

50

[55]

 

0/4

0

[56]

 

6/17

35

[57]

Overall BRAFV600E

21/89

23

 

RAS

4/50

8

[44]

 

2/18

11

[58]

 

1/5

20

[59]

 

4/18

23

[43]

 

15/29

55

[60]

 

4/50

8

[61]

 

3/5

60

[62]

Overall RAS mutations

33/162

20

 

RET/PTC

0/14

0

[63]

 

3/51

6

[44]

 

0/17

0

[64]

Overall RET/PTC

3/81

4

Â